Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 79

1.

[Non-rational recommendation for pioglitazone in diabetic steatohepatitis].

Lindberg M.

Ugeskr Laeger. 2012 Mar 19;174(12):819; author reply 819. Danish. No abstract available.

PMID:
22540134
[PubMed - indexed for MEDLINE]
2.

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.

Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, Balas B, Gastaldelli A, Tio F, Pulcini J, Berria R, Ma JZ, Dwivedi S, Havranek R, Fincke C, DeFronzo R, Bannayan GA, Schenker S, Cusi K.

N Engl J Med. 2006 Nov 30;355(22):2297-307.

PMID:
17135584
[PubMed - indexed for MEDLINE]
Free Article
3.

Effect of pioglitazone on biochemical indices of non-alcoholic fatty liver disease in upper body obesity.

Shadid S, Jensen MD.

Clin Gastroenterol Hepatol. 2003 Sep;1(5):384-7.

PMID:
15017657
[PubMed - indexed for MEDLINE]
4.

[Steatosis and steatohepatitis in diabetic patient].

Hůlek P, Dresslerová I.

Vnitr Lek. 2011 Apr;57(4):364-7. Review. Czech.

PMID:
21612059
[PubMed - indexed for MEDLINE]
5.

Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis.

Aithal GP, Thomas JA, Kaye PV, Lawson A, Ryder SD, Spendlove I, Austin AS, Freeman JG, Morgan L, Webber J.

Gastroenterology. 2008 Oct;135(4):1176-84. doi: 10.1053/j.gastro.2008.06.047. Epub 2008 Jun 25.

PMID:
18718471
[PubMed - indexed for MEDLINE]
6.

Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholic steatohepatitis.

Balas B, Belfort R, Harrison SA, Darland C, Finch J, Schenker S, Gastaldelli A, Cusi K.

J Hepatol. 2007 Oct;47(4):565-70. Epub 2007 May 24.

PMID:
17560678
[PubMed - indexed for MEDLINE]
7.

Roles of adipose restriction and metabolic factors in progression of steatosis to steatohepatitis in obese, diabetic mice.

Larter CZ, Yeh MM, Van Rooyen DM, Teoh NC, Brooling J, Hou JY, Williams J, Clyne M, Nolan CJ, Farrell GC.

J Gastroenterol Hepatol. 2009 Oct;24(10):1658-68. doi: 10.1111/j.1440-1746.2009.05996.x.

PMID:
19788606
[PubMed - indexed for MEDLINE]
8.

Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis.

Ota T, Takamura T, Kurita S, Matsuzawa N, Kita Y, Uno M, Akahori H, Misu H, Sakurai M, Zen Y, Nakanuma Y, Kaneko S.

Gastroenterology. 2007 Jan;132(1):282-93. Epub 2006 Oct 12.

PMID:
17241878
[PubMed - indexed for MEDLINE]
9.

[Prognosis and treatment of non-alcoholic fatty liver disease and steatohepatitis].

Heebøll S, Kazankov K, Poulsen MK, Vilstrup H, Grønbæk H.

Ugeskr Laeger. 2012 Feb 20;174(8):488-90. Danish.

PMID:
22348670
[PubMed - indexed for MEDLINE]
10.

Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study.

Hasegawa T, Yoneda M, Nakamura K, Makino I, Terano A.

Aliment Pharmacol Ther. 2001 Oct;15(10):1667-72.

PMID:
11564008
[PubMed - indexed for MEDLINE]
Free Article
11.

Pioglitazone ameliorates nonalcoholic steatohepatitis by down-regulating hepatic nuclear factor-kappa B and cyclooxygenases-2 expression in rats.

Zhao JS, Zhu FS, Liu S, Yang CQ, Chen XM.

Chin Med J (Engl). 2012 Jul;125(13):2316-21.

PMID:
22882855
[PubMed - indexed for MEDLINE]
Free Article
12.

Pioglitazone in nonalcoholic steatohepatitis.

Targher G.

N Engl J Med. 2007 Mar 8;356(10):1067; author reply 1068-9. No abstract available.

PMID:
17347462
[PubMed - indexed for MEDLINE]
Free Article
13.

[Insulin sensitizer--anti-diabetic drugs, metformin and pioglitazone that can improve insulin resistance].

Korenaga M, Kawaguchi K, Korenaga K, Uchida K, Sakaida I.

Nihon Rinsho. 2006 Jun;64(6):1157-64. Review. Japanese.

PMID:
16768125
[PubMed - indexed for MEDLINE]
14.

Pioglitazone in nonalcoholic steatohepatitis.

Chavez-Tapia NC, Barrientos-Gutierrez T, Uribe M.

N Engl J Med. 2007 Mar 8;356(10):1067-8; author reply 1068-9. No abstract available.

PMID:
17354302
[PubMed - indexed for MEDLINE]
15.

Evaluation and management of non-alcoholic steatohepatitis.

Reid BM, Sanyal AJ.

Eur J Gastroenterol Hepatol. 2004 Nov;16(11):1117-22. Review.

PMID:
15489568
[PubMed - indexed for MEDLINE]
16.

Pioglitazone prevents hepatic steatosis, fibrosis, and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet.

Kawaguchi K, Sakaida I, Tsuchiya M, Omori K, Takami T, Okita K.

Biochem Biophys Res Commun. 2004 Feb 27;315(1):187-95.

PMID:
15013444
[PubMed - indexed for MEDLINE]
17.

Elevated plasma homocysteine concentrations as a predictor of steatohepatitis in patients with non-alcoholic fatty liver disease.

Gulsen M, Yesilova Z, Bagci S, Uygun A, Ozcan A, Ercin CN, Erdil A, Sanisoglu SY, Cakir E, Ates Y, Erbil MK, Karaeren N, Dagalp K.

J Gastroenterol Hepatol. 2005 Sep;20(9):1448-55.

PMID:
16105135
[PubMed - indexed for MEDLINE]
18.

Pioglitazone in nonalcoholic steatohepatitis.

Ota T, Takamura T, Kaneko S.

N Engl J Med. 2007 Mar 8;356(10):1068; author reply 1068-9. No abstract available.

PMID:
17354303
[PubMed - indexed for MEDLINE]
19.

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.

Violi F, Cangemi R.

N Engl J Med. 2010 Sep 16;363(12):1185-6; author reply 1186. No abstract available.

PMID:
20857543
[PubMed - indexed for MEDLINE]
20.

[PPAR gamma ligand pioglitazone as a therapeutic strategy in nonalcoholic steatohepatitis (NASH)].

Yoneda M, Fujita K, Nakajima A, Wada K.

Nihon Yakurigaku Zasshi. 2006 Oct;128(4):235-8. Review. Japanese. No abstract available.

PMID:
17038787
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk